Northrop Grumman and Rhodium Scientific to Collaborate on Bio-Tech and Bio-Pharma Research in Low-Earth Orbit
Northrop Grumman and Rhodium Scientific announced a collaboration to conduct market analysis on the scientific research market in low Earth orbit. Rhodium also expressed its interest in utilizing Northrop Grumman’s Space Station concept for science experiment facilitation. In December 2021, Northrop Grumman signed a Space Act Agreement with NASA under the Commercial Low-Earth Orbit Development program for $125.6 million to design a safe, reliable and cost-effective commercial free-flying space station in low Earth orbit (LEO).
This collaboration establishes Rhodium Scientific’s intention to utilize Northrop Grumman’s commercial space station concept as one of the LEO destinations capable of supporting their portfolio of scientific, flight-centered hardware. The collaboration also underscores the potential for Rhodium Scientific to continue science, biopharma and biomanufacturing missions currently being undertaken on the International Space Station on the Northrop Grumman space station concept. This collaboration will explore not only the potential to translate that research into useful products on Earth but also further develop the bio-tech research market in low Earth orbit and translate and mature Earth-based technical requirements to meet on-orbit science operations, helping to support a new space-based research economy.
About Northrop Grumman
Northrop Grumman is a technology company focused on global security and human discovery. Our pioneering solutions equip our customers with capabilities they need to connect, advance and protect the U.S. and its allies. Driven by a shared purpose to solve our customers’ toughest problems, our 90,000 employees define possible every day.
Rhodium Scientific is an international bio-technology company located in Houston. The company is a woman, Hispanic-owned small business, specializing in life science services, mission integration and operation, and a hardware portfolio that enables the frontier of microgravity research and production. Since 2014, the company has developed and managed more than 400 scientific projects, facilitated more than 20 missions to space, and established a portfolio of flight-certified hardware capable of facilitating a broad range of biotech industry requirements.